Oritavancin

Drug Profile

Oritavancin

Alternative Names: LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; Ramvocid

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer The Medicines Company
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • No development reported Anthrax; Clostridium infections; Gram-positive infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gram-positive-infections(In adolescents, In children) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in USA (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Clostridium-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top